JamesW.BakerMD

Allergy & Immunology • Portland, OR

Asthma & Allergic Conditions, Pediatric Asthma & Allergic Conditions

Physician

Join to view full profile

Dr. Baker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Baker's full profile

Already have an account?

Office
9495 SW Locust St
Ste A
Portland, OR 97223
Phone+1 503-636-9011

Fax+1 503-636-3952
Is this information wrong?

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Allergy and Immunology, 1971 - 1974
University of Vermont Medical CenterInternship, Internal Medicine, 1970 - 1971
University of Wisconsin School of Medicine & Public HealthClass of 1970

Certifications & Licensure

OR State Medical License 1974 - 2025
WI State Medical License 1971 - 1975
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Top MD Consumers Checkbook

Clinical Trials

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Start of enrollment: 2014 May 14
Completed
Phase 1

Publications & Presentations

PubMed

7 citations
Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks.
James W. Baker, Jonathan A. Bernstein, Joseph R. Harper, Anurag Relan, Marc A. Riedl> ;Allergy and Asthma Proceedings. 2018 Sep 28
23 citations
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Marc A. Riedl, Emel Aygören-Pürsün, James R. Baker, Henriette Farkas, John Anderson, Jonathan A. Bernstein, Laurence Bouillet, Paula J. Busse, Michael E. Manning, Mark...> ;Allergy. 2018 Sep 1
7 citations
Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks.
H. Henry Li, Avner Reshef, James W. Baker, Joseph R. Harper, Anurag Relan> ;Allergy and Asthma Proceedings. 2017 Nov 5
8 citations
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents
James W. Baker, Avner Reshef, Dumitru Moldovan, Joseph R. Harper, Anurag Relan, Marc A. Riedl> ;The Journal of Allergy and Clinical Immunology. in Practice. 2017 Jul 1
13 citations
Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients
Paula J. Busse, James W. Baker, Inmaculada Martinez-Saguer, Jonathan A. Bernstein, Timothy J. Craig, Markus Magerl, Marc A. Riedl, Ralph Shapiro, Michael M. Frank, Wil...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2017 Jul 1
13 citations
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.
Timothy J. Craig, Ralph Shapiro, Arthur B. Vegh, James W. Baker, Jonathan A. Bernstein, Paula J. Busse, Markus Magerl, Inmaculada Martinez-Saguer, Marc A. Riedl, Willi...> ;Allergy & Rhinology. 2017 Mar 1
29 citations
Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.
Li, H. H., Moldovan, D., Bernstein, J. A., Reshef, A., Porebski, G., Stobiecki, M., Baker, J., Levy, R., Relan, A., Riedl, M.> ;The journal of allergy and clinical immunology. In practice. 2015 Feb 15
80 citations
Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-treated Reactions
Richard L. Wasserman, Jeffrey M. Factor, James W. Baker, Lyndon E. Mansfield, Yitzhak Katz, Angela R. Hague, Marianne M. Paul, Robert W. Sugerman, Jason O. Lee, Mitche...> ;The Journal of Allergy and Clinical Immunology. in Practice. 2014 Jan 1
44 citations
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study
Marc A. Riedl, Robyn J. Levy, Daniel Suez, Richard F. Lockey, James W. Baker, Anurag Relan, Bruce L. Zuraw> ;Annals of Allergy, Asthma & Immunology. 2013 Apr 1
15 citations
Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women.
James W. Baker, Timothy J. Craig, Marc A. Riedl, Aleena Banerji, David Fitts, Ira Kalfus, Marc E. Uknis> ;Allergy and Asthma Proceedings. 2013 Mar 1
15 citations
Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma
Stanley J. Szefler, Lars-Goran Carlsson, Tom Uryniak, James W. Baker> ;The Journal of Allergy and Clinical Immunology. in Practice. 2013 Jan 1
17 citations
Office-based oral immunotherapy for food allergy is safe and effective.
Richard L. Wasserman, Robert W. Sugerman, Nana Mireku-Akomeah, Lyndon E. Mansfield, James W. Baker> ;The Journal of Allergy and Clinical Immunology. 2011 Jan 1
3 citations
Safety of Daily Albuterol in Infants with a History of Bronchospasm: A Multi-Center Placebo Controlled Trial
James A Hedrick, James W. Baker, Arthur B Atlas, Aftab A Naz, W. Lincourt, Roopa Trivedi, Anna Ellworth, Angela M. Davis> ;The Open Respiratory Medicine Journal. 2009 Jul 16
3 citations
Asthma control in pediatric patients treated with once-daily or twice-daily nebulized budesonide inhalation suspension (Pulmicort Respules).
James W. Baker, James P. Kemp, Tom Uryniak, Philip E. Silkoff> ;Allergy and Asthma Proceedings. 2008 May 1
75 citations
Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma.
Stanley J. Szefler, James W. Baker, Tom Uryniak, Mitchell Goldman, Philip E. Silkoff> ;The Journal of Allergy and Clinical Immunology. 2007 Nov 1
34 citations
Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
Richard L. Wasserman, James W. Baker, Kenneth Kim, Kathryn V. Blake, Catherine Scott, W. Wu, Melissa A. Faris, Courtney Crim> ;Annals of Allergy, Asthma & Immunology. 2006 Jun 1
86 citations
Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma
Brian J. Lipworth, Michael A. Kaliner, Craig LaForce, James W. Baker, Harold B. Kaiser, Dilip Amin, S. Kundu, James Williams, Renate Engelstaetter, Donald Banerji> ;Annals of Allergy, Asthma & Immunology. 2005 Apr 1
16 citations
Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study.
Robert S. Zeiger, James W. Baker, Michael S. Kaplan, David S. Pearlman, Michael Schatz, Steven R. Bird, Carolyn M. Hustad, Jonathan M. Edelman> ;Respiratory Medicine. 2004 Sep 1
24 citations
A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma.
Gordon D. Raphael, Robert Q. Lanier, James W. Baker, Lisa D. Edwards, Kathy Rickard, William Lincourt> ;The Journal of Allergy and Clinical Immunology. 1999 May 1
25 citations
Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: Tachyphylaxis after theophylline therapy
Thomas A. Giustina, Sai C. Chan, Marcella L. Thiel, James W. Baker, Jon M. Hanifin> ;The Journal of Allergy and Clinical Immunology. 1984 Sep 1
153 citations
Rhinovirus and influenza type A infections as precipitants of asthma.
Theodore E. Minor, Elliot C. Dick, James W. Baker, John J. Ouellette, Marcus Cohen, Charles E. Reed> ;The American Review of Respiratory Disease. 1976 Feb 1
107 citations
Greater frequency of viral respiratory infections in asthmatic children as compared with their nonasthmatic siblings.
Theodore E. Minor, James W. Baker, Elliot C. Dick, Anthony N. DeMeo, John J. Ouellette, Marcus Cohen, Charles E. Reed> ;The Journal of Pediatrics. 1974 Oct 1
Join now to see all

Press Mentions

Faster Relief of HAE Attacks Seen with Recombinant Human C1 Esterase InhibitorMarch 6th, 2017
Xtract Solutions Will Join Health Care Leaders from Across the Globe at Cerner Health Conference 2018October 8th, 2011